Iradimed CORP 10-Q quarterly reports

IRadimed Corporation announced its second quarter 2026 financial results, showing a slight increase in revenue and a decrease in net income compared to the prior year period.

IRADIMED Corporation reported a strong third quarter 2025 with revenue increasing 16% to $21.2 million and diluted EPS rising to $0.43, driven by demand for MRI-compatible medical devices.

IRADIMED Corporation announced robust financial results for Q2 2025, driven by increased domestic sales and the recent FDA clearance of its next-generation MRidium 3870 IV infusion pump system.

IRADIMED Corporation announces an 11% increase in revenue for the first quarter of 2025, fueled by robust sales of its MRI compatible medical devices and related products.

IRADIMED Corporation's Q3 2024 results show an 11% increase in revenue compared to the same period last year, driven by strong demand for its MRI compatible medical devices.

IRADIMED Corporation's Q2 2024 revenue increased by 11.2% year-over-year, driven by strong sales of its MRI compatible medical devices.

IRADIMED Corporation's first quarter 2024 revenue increased by 13.7% year-over-year, driven by strong sales of patient vital signs monitoring systems and disposables.